Cyclic Prosaposin Peptides for Stable Tsp-1 Stimulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancer and inflammatory diseases are either ineffective or have undesirable side-effects, and existing linear prosaposin peptides do not provide optimal stability and efficacy.
Innovation Solution
The use of cyclic prosaposin peptides, particularly DWLPK (SEQ ID NO: 1), which are more stable and effective than linear peptides, stimulate thrombospondin-1 (Tsp-1) expression, reducing inflammation and treating conditions like Crohn's disease, cancer, and other inflammatory disorders without toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If linear prosaposin peptides are used, then they can stimulate Tsp-1 expression, but they have poor stability and suboptimal efficacy
Solution Approach 1:
The patent applies parameter changes by modifying the peptide structure from linear to cyclic form. This structural parameter change dramatically improves stability while maintaining Tsp-1 stimulation capability. The cyclic structure prevents proteolytic degradation and extends half-life in serum, directly resolving the stability issue of linear peptides.
Solution Approach 2:
The patent creates a composite peptide structure by combining specific amino acid sequences (DWLPK or DWGPK) with cyclic conformational constraints. This composite approach integrates the stabilizing effect of cyclization with the bioactive sequence, achieving both stability and efficacy simultaneously.
2Reliability
If cyclic DWLPK peptide is used, then it is more stable and effective, but the structure is more complex to manufacture
Solution Approach 1:
The patent segments the peptide synthesis process into two distinct stages: first synthesizing the linear peptide sequence using standard solid-phase peptide synthesis methods, then separately performing the cyclization step. This segmentation allows each step to be optimized independently, reducing overall manufacturing complexity despite the cyclic final structure.
Solution Approach 2:
The patent applies preliminary action by completing the linear peptide synthesis first with all amino acids in place, then performing cyclization as a final step. This preliminary arrangement of the linear sequence simplifies the synthesis process compared to attempting to assemble the cyclic structure directly, as standard linear synthesis techniques can be used initially.
3Reliability
If linear DWGPK peptide is used, then it shows better activity than linear DWLPK, but cyclic DWLPK shows better activity than cyclic DWGPK
Solution Approach 1:
The patent applies dynamics by demonstrating that the cyclic structure introduces conformational constraints that change how the peptide interacts with Tsp-1. The cyclization creates a rigidified structure where the spatial arrangement of residues becomes critical, making the system's activity dependent on three-dimensional configuration rather than just primary sequence, thus explaining the reversal of activity preferences between DWLPK and DWGPK upon cyclization.
Data Source
AI summary
Provided herein are cyclic prosaposin peptides and compositions and uses thereof. Exemplary uses include use in the treatment of cancer or in the treatment of inflammatory diseases or disorders.